HomeTrialNCT07346495
🔬NCT07346495Phase 1RECRUITING

A Study of Remternetug (LY3372993) in Healthy Chinese Participants

Study Summary

The study will evaluate the safety and tolerability of remternetug when given subcutaneously (SC) (under the skin) to healthy Chinese participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last up to 25 weeks, including screening period.

Conditions
Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment24 participants
Primary Completion
Lead SponsorEli Lilly and Company
Data Retrieved2026-04-11 02:55:33.865530+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.